Caribou Biosciences

CRBU

市值 US$5038萬

U.S. stock futures were lower this morning, with the Dow futures falling around 450 points on Thursday.

-- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs --

The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Top-ranked stocks ALL, W, BILL, TWLO and CRBU are likely to beat on the bottom line in their upcoming releases.

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.35 per share a year ago.

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL -- -- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 -- BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the second quarter of 2026 and provided a business update.

Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the H.C.

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case study of a patient who previously received an anti-BCMA CAR-T showed an early complete response that was ongoing as of the data cutoff date --